---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-222962"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2024-09-20T23:59:59+00:00"
generated_at: "2026-05-31T02:45:53.409405+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences appoints Richard Vincent and Shiv Kapoor to board; settles Camac lawsuit for $1.5M

## Summary
- Donald A. Williams and Lawrence Eichenfield resigned from board effective Sept 17, 2024, not due to any disagreement.
- Richard Vincent and Shiv Kapoor appointed as Class II directors; to stand for election at 2025 annual meeting.
- Steven Kornfeld and Scott Brun reclassified from Class II to Class III to maintain class sizes.
- Camac Fund lawsuit settled; company to pay $1.5M for attorneys' fees; case dismissed with prejudice as to Camac; Standstill Agreement stands.
- Board established Strategic Committee of independent directors; Rights Agreement (poison pill) expired July 12, 2024, not renewed.

## SEC filing metadata
- accession: 0001193125-24-222962
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2024-09-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312524222962/0001193125-24-222962-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312524222962/d844019d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-222962
- JSON: https://secwatch.observer/filing/0001193125-24-222962.json
- Plain text: https://secwatch.observer/filing/0001193125-24-222962.txt

## Key facts
- Executive change
  Lawrence Eichenfield resigned as Director at Forte Biosciences, Inc..
  - Action: resigned
  - Role: Director
  source text: On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312524222962/0001193125-24-222962-index.htm
- Executive change
  Richard Vincent was appointed as Director at Forte Biosciences, Inc..
  - Action: appointed
  - Role: Director
  source text: On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312524222962/0001193125-24-222962-index.htm
- Executive change
  Donald A. Williams resigned as Director at Forte Biosciences, Inc..
  - Action: resigned
  - Role: Director
  source text: On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312524222962/0001193125-24-222962-index.htm
- Executive change
  Shiv Kapoor was appointed as Director at Forte Biosciences, Inc..
  - Action: appointed
  - Role: Director
  source text: On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312524222962/0001193125-24-222962-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.